Security Snapshot

TREACE MEDICAL CONCEPTS, INC. - Common stock, $0.001 par value (TMCI) Institutional Ownership

CUSIP: 89455T109

13F Institutional Holders and Ownership History from Q1 2019 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

117

Shares (Excl. Options)

31,859,778

Price

$3.98

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-4,083,541
Value change
-$13,977,549
Number of holders
117
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
65,005,107
SEC-reported price per share
$4.23
Insider filing price
$4.23
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • TMCI - TREACE MEDICAL CONCEPTS, INC. - Common stock, $0.001 par value is tracked under CUSIP 89455T109.
  • 117 institutions reported positions in Q2 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 116 to 117 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $48,145,260 to $126,819,910.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 117 institutions filings for Q2 2026.

Open SEC evidence

Security key

89455T109

Latest holder period

Q2 2026

13F holders

117

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
TMCI
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Treace John T. 19% $58,394,269 12,530,959 John T. Treace 30 Jun 2026
ARMISTICE CAPITAL, LLC 9.8% -0.6% $29,656,240 6,364,000 0% Armistice Capital, LLC 30 Jun 2026
GAGNON SECURITIES LLC 9.6% +55% $15,355,268 +$5,406,632 6,142,107 +54% Neil Gagnon 31 Dec 2025
BANK OF AMERICA CORP /DE/ 5.5% $7,102,886 3,533,774 BANK OF AMERICA CORP /DE/ 31 Mar 2026
MORGAN STANLEY 3.4% $13,931,448 2,091,809 Morgan Stanley 31 Dec 2024
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.8% -67% $2,863,745 -$6,297,435 1,145,498 -69% WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 31 Dec 2025
BlackRock, Inc. 1.5% $3,818,094 959,320 BlackRock, Inc. 30 Jun 2026

As of 30 Jun 2026, 117 institutional investors reported holding 31,859,778 shares of TREACE MEDICAL CONCEPTS, INC. - Common stock, $0.001 par value (TMCI). This represents 49% of the company’s total 65,005,107 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
45%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARMISTICE CAPITAL, LLC 9.8% 6,364,000 0% 0.7% $25,328,720
BANK OF AMERICA CORP /DE/ 5.1% 3,305,100 +2.8% 0% $13,154,298
GAGNON SECURITIES LLC 4.7% 3,029,543 -42% 2.3% $12,057,581
VANGUARD CAPITAL MANAGEMENT LLC 3.1% 2,028,479 +39% 0% $8,073,346
Gagnon Advisors, LLC 2.4% 1,534,034 3.9% $6,105,455
AQR CAPITAL MANAGEMENT LLC 2.3% 1,497,673 +41% 0% $5,960,738
BlackRock, Inc. 2.1% 1,380,021 -59% 0% $5,492,483
MARSHALL WACE, LLP 2% 1,328,592 +401% 0% $5,287,797
CIBC Bancorp USA Inc. 1.9% 1,216,044 -0.19% 0.01% $4,839,856
ACADIAN ASSET MANAGEMENT LLC 1.4% 928,177 -1.4% 0% $3,688,000
MILLENNIUM MANAGEMENT LLC 1.1% 738,628 -36% 0% $2,939,739
WEBER CAPITAL MANAGEMENT LLC /ADV 0.91% 589,617 0% 2% $2,346,676
D. E. Shaw & Co., Inc. 0.9% 583,277 -31% 0% $2,321,442
GEODE CAPITAL MANAGEMENT, LLC 0.88% 573,796 -43% 0% $2,284,531
CITADEL ADVISORS LLC 0.8% 516,994 -37% 0% $2,057,636
GOLDMAN SACHS GROUP INC 0.76% 492,116 +27% 0% $1,958,621
STIFEL FINANCIAL CORP 0.67% 435,009 +147% 0% $1,731,337
UBS Group AG 0.56% 366,445 -33% 0% $1,458,451
JACOBS LEVY EQUITY MANAGEMENT, INC 0.56% 363,729 +38% 0.01% $1,447,641
RAYMOND JAMES FINANCIAL INC 0.51% 331,110 -7.4% 0% $1,317,818
MORGAN STANLEY 0.49% 320,026 +46% 0% $1,273,704
VANGUARD FIDUCIARY TRUST CO 0.45% 292,504 -8% 0% $1,164,166
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.43% 282,538 -14% 0% $1,124,501
STATE STREET CORP 0.36% 234,271 -81% 0% $932,399
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.33% 214,219 +1156% 0% $852,592

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
30
Latest
Q2 2026
Rows shown
1-25 of 30
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 31,859,778 $126,819,910 -$13,977,549 $3.98 117
2026 Q1 35,922,570 $48,145,260 -$3,585,169 $1.34 116
2025 Q4 35,847,129 $87,953,121 -$21,913,008 $2.45 114
2025 Q3 38,823,239 $260,292,697 +$3,224,800 $6.71 117
2025 Q2 38,411,285 $225,932,843 +$594,572 $5.88 122
2025 Q1 37,892,233 $314,933,438 +$6,396,329 $8.39 136
2024 Q4 37,307,543 $277,767,394 -$15,594,697 $7.44 133
2024 Q3 39,629,299 $229,799,434 +$2,450,302 $5.80 133
2024 Q2 39,705,068 $264,072,594 -$75,189,680 $6.65 126
2024 Q1 41,245,049 $537,228,351 +$3,488,774 $13.05 129
2023 Q4 41,010,068 $522,886,552 +$21,281,231 $12.75 126
2023 Q3 39,193,648 $513,809,790 -$36,596,248 $13.11 121
2023 Q2 38,926,750 $995,556,262 +$84,284,218 $25.58 135
2023 Q1 35,535,142 $895,139,591 +$184,017,260 $25.19 122
2022 Q4 26,874,663 $617,852,430 +$44,023,715 $22.99 105
2022 Q3 26,104,333 $576,118,458 +$73,324,010 $22.07 90
2022 Q2 23,108,213 $331,376,313 +$38,889,452 $14.34 81
2022 Q1 20,370,513 $385,285,843 +$38,473,149 $18.91 74
2021 Q4 17,228,093 $320,930,460 +$66,992,636 $18.64 74
2021 Q3 13,036,758 $350,676,095 -$6,970,436 $26.90 61
2021 Q2 13,009,799 $406,683,468 +$406,677,512 $31.26 70
2021 Q1 179 $6,000 $33.52 1
2020 Q4 179 $6,000 $33.52 1
2020 Q3 179 $6,000 $33.52 1
2020 Q2 179 $6,000 $33.52 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .